Moderna Stock

Moderna FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Moderna (MRNA) as of Aug 3, 2026 is 73.18 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 113.87 % — a change of -35.74% (lower).

FCF Conversion

73.18 %

YoY

-35.74%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Moderna is 2026 73.18 % . FCF Conversion Rate (FCF/EBITDA) of Moderna was 2025 113.87 % . It decreases by -35.74% lower compared to the previous year.
Access this data via the Eulerpool API

Moderna Stock analysis

What does Moderna do? Moderna Inc is a biotechnology company from the USA that specializes in the development of therapies and vaccines based on mRNA technology. The company was founded in 2010 by a group of researchers led by Noubar Afeyan and is headquartered in Cambridge, Massachusetts. Moderna is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Moderna stock

FCF Conversion Rate (FCF/EBITDA) of Moderna is 73.18 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Moderna changed from 113.87 % to 73.18 %, representing a -35.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Moderna since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Moderna with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Moderna

All Key Metrics — Moderna